{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:36:37Z","timestamp":1793338597757,"version":"4.5.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Because protein function regulates the phenotypic characteristics of cancer, a functional proteomic classification system could provide important information for pathogenesis and prognosis. With the goal of ultimately developing a proteomic-based classification of acute myeloid leukemia (AML), we assayed leukemia-enriched cells from 256 newly diagnosed AML patients, for 51 total and phosphoproteins from apoptosis, cell-cycle, and signal-transduction pathways, using reverse-phase protein arrays. Expression in matched blood and marrow samples were similar for 44 proteins; another 7 had small fold changes (8%-55%), suggesting that functional proteomics of leukemia-enriched cells in the marrow and periphery are similar. Protein expression patterns were independent of clinical characteristics. However, 24 proteins were significantly different between French-American-British subtypes, defining distinct signatures for each. Expression signatures for AML with cytogenetic abnormalities involving \u22125 or \u22127 were similar suggesting mechanistic commonalities. Distinct expression patterns for FMS-like tyrosine kinase 3\u2013internal tandem duplication were also identified. Principal component analysis defined 7 protein signature groups, with prognostic information distinct from cytogenetics that correlated with remission attainment, relapse, and overall survival. In conclusion, protein expression profiling patterns in AML correlate with known morphologic features, cytogenetics, and outcome. Confirmation in independent studies may also provide pathophysiologic insights facilitating triage of patients to emerging targeted therapies.<\/jats:p>","DOI":"10.1182\/blood-2007-10-119438","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T00:44:35Z","timestamp":1223426675000},"page":"154-164","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":225,"title":["Functional proteomic profiling of AML predicts response and survival"],"prefix":"10.1182","volume":"113","author":[{"given":"Steven M.","family":"Kornblau","sequence":"first","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Tibes","sequence":"additional","affiliation":[{"name":"Translational Genomics Research Institute, Phoenix\/Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Hua","family":"Qiu","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Chen","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Departments of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[{"name":"Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Coombes","sequence":"additional","affiliation":[{"name":"Bioinformatics and Computational Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon B.","family":"Mills","sequence":"additional","affiliation":[{"name":"Systems Biology, University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713001696800_B1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2006-06-001149","article-title":"Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?","volume":"109","author":"Mrozek","year":"2007","journal-title":"Blood"},{"key":"2019111713001696800_B2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer.","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"2019111713001696800_B3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer.","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"2019111713001696800_B4","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1038\/sj.onc.1210758","article-title":"Aberrant cytokine signaling in leukemia.","volume":"26","author":"Van Etten","year":"2007","journal-title":"Oncogene"},{"key":"2019111713001696800_B5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V84.1.256.256","article-title":"Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia.","volume":"84","author":"Kornblau","year":"1994","journal-title":"Blood"},{"key":"2019111713001696800_B6","first-page":"1401","article-title":"BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.","volume":"6","author":"Kornblau","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2019111713001696800_B7","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2006-02-003475","article-title":"Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.","volume":"108","author":"Kornblau","year":"2006","journal-title":"Blood"},{"key":"2019111713001696800_B8","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2404384","article-title":"Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia.","volume":"20","author":"Kreuter","year":"2006","journal-title":"Leukemia"},{"key":"2019111713001696800_B9","doi-asserted-by":"crossref","first-page":"13901","DOI":"10.1073\/pnas.241525498","article-title":"BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia.","volume":"98","author":"Tanner","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713001696800_B10","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"2019111713001696800_B11","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMoa031046","article-title":"Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.","volume":"350","author":"Bullinger","year":"2004","journal-title":"N Engl J Med"},{"key":"2019111713001696800_B12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa040465","article-title":"Prognostically useful gene-expression profiles in acute myeloid leukemia.","volume":"350","author":"Valk","year":"2004","journal-title":"N Engl J Med"},{"key":"2019111713001696800_B13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccr.2005.10.001","article-title":"Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.","volume":"8","author":"Varambally","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111713001696800_B14","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1074\/mcp.M400055-MCP200","article-title":"Integrated genomic and proteomic analyses of gene expression in mammalian cells.","volume":"3","author":"Tian","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"2019111713001696800_B15","doi-asserted-by":"crossref","first-page":"14229","DOI":"10.1073\/pnas.2331323100","article-title":"Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays.","volume":"100","author":"Nishizuka","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713001696800_B16","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"2019111713001696800_B17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0076-6879(05)03017-X","article-title":"Assay of Rab25 function in ovarian and breast cancers.","volume":"403","author":"Cheng","year":"2005","journal-title":"Methods Enzymol"},{"key":"2019111713001696800_B18","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","article-title":"Reverse phase protein array (RPPA): validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoetic stem cells (HSC).","volume":"5","author":"Tibes","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2019111713001696800_B19","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/sj.onc.1204265","article-title":"Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front.","volume":"20","author":"Paweletz","year":"2001","journal-title":"Oncogene"},{"key":"2019111713001696800_B20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1074\/mcp.T500003-MCP200","article-title":"Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.","volume":"4","author":"Sheehan","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"2019111713001696800_B21","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/pmic.200300598","article-title":"Signal pathway profiling of prostate cancer using reverse phase protein arrays.","volume":"3","author":"Grubb","year":"2003","journal-title":"Proteomics"},{"key":"2019111713001696800_B22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/44.12.8985127","article-title":"Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining.","volume":"44","author":"Hunyady","year":"1996","journal-title":"J Histochem Cytochem"},{"key":"2019111713001696800_B23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/bfgp\/1.3.305","article-title":"Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays.","volume":"1","author":"Charboneau","year":"2002","journal-title":"Brief Funct Genomic Proteomic"},{"key":"2019111713001696800_B24","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1109\/TSP.2006.873719","article-title":"Nonlinear modeling of protein expression in protein arrays.","volume":"54","author":"Tabus","year":"2006","journal-title":"IEEE Trans Signal Process"},{"key":"2019111713001696800_B25","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1073\/pnas.161273698","article-title":"Bootstrapping cluster analysis: assessing the reliability of conclusions from microarray experiments.","volume":"98","author":"Kerr","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713001696800_B26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/1467-9868.00293","article-title":"Estimating the number of clusters in a data set via the gap statistic.","volume":"63","author":"Tibshirani","year":"2001","journal-title":"J R Stat Soc Series"},{"key":"2019111713001696800_B27","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/sj.leu.2403845","article-title":"Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia.","volume":"19","author":"Kornblau","year":"2005","journal-title":"Leukemia"},{"key":"2019111713001696800_B28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood.V73.1.263.263","article-title":"Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia.","volume":"73","author":"Schiffer","year":"1989","journal-title":"Blood"},{"key":"2019111713001696800_B29","first-page":"2140","article-title":"Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.","volume":"9","author":"Spiekermann","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2019111713001696800_B30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.onc.1203354","article-title":"Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.","volume":"19","author":"Hayakawa","year":"2000","journal-title":"Oncogene"},{"key":"2019111713001696800_B31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","article-title":"AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.","volume":"106","author":"Choudhary","year":"2005","journal-title":"Blood"},{"key":"2019111713001696800_B32","volume-title":"Bayesian Data Analysis","author":"Gelman","year":"2004","edition":"2nd ed"},{"key":"2019111713001696800_B33","first-page":"108","article-title":"Mutations of the Tp53 gene occur in 13.4% of acute myeloid leukemia and are strongly associated with a complex aberrant karyotype [abstract].","author":"Schoch","year":"2006","journal-title":"Blood"},{"key":"2019111713001696800_B34","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1073\/pnas.0507493103","article-title":"Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.","volume":"103","author":"Tovar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713001696800_B35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1365-2141.2000.02328.x","article-title":"Expression and prognostic significance of survivin in de novo acute myeloid leukaemia.","volume":"111","author":"Adida","year":"2000","journal-title":"Br J Haematol"},{"key":"2019111713001696800_B36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2141.1992.tb08897.x","article-title":"Mutations of the p53 gene in acute myeloid leukaemia.","volume":"80","author":"Fenaux","year":"1992","journal-title":"Br J Haematol"},{"key":"2019111713001696800_B37","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","article-title":"p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.","volume":"84","author":"Wattel","year":"1994","journal-title":"Blood"},{"key":"2019111713001696800_B38","article-title":"p53 protein expression levels are prognostic in AML and predict for mutational status [abstract].","author":"Kornblau"},{"key":"2019111713001696800_B39","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"key":"2019111713001696800_B40","doi-asserted-by":"crossref","first-page":"10857","DOI":"10.1073\/pnas.191117498","article-title":"Inhibition of both paracrine and autocrine VEGF\/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.","volume":"98","author":"Dias","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713001696800_B41","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1182\/blood.V100.13.4622","article-title":"In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo.","volume":"100","author":"Schuch","year":"2002","journal-title":"Blood"},{"key":"2019111713001696800_B42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-5793(01)02242-6","article-title":"Protein kinase B (PKB\/Akt): a key regulator of glucose transport?","volume":"492","author":"Hajduch","year":"2001","journal-title":"FEBS Lett"},{"key":"2019111713001696800_B43","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","article-title":"New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway.","volume":"96","author":"Cantley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713001696800_B44","doi-asserted-by":"crossref","first-page":"15587","DOI":"10.1073\/pnas.95.26.15587","article-title":"The PTEN\/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase\/Akt pathway.","volume":"95","author":"Wu","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713001696800_B45","doi-asserted-by":"crossref","article-title":"Patterns and prognostic impact of PI3K-AKT pathway activation, regulation and downstream activity in AML using reverse phase proteins arrays (RPPA) [abstract]","author":"Kornblau","DOI":"10.1182\/blood.V110.11.2393.2393"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/1\/154\/1303434\/zh800109000154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/1\/154\/1303434\/zh800109000154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T08:15:43Z","timestamp":1684570543000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/1\/154\/24404\/Functional-proteomic-profiling-of-AML-predicts"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-10-119438","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}